Francart et al developed models for predicting progression-free and overall survival for patients with malignant mesothelioma enrolled in EORTC trials. The authors are from multiple institutions in Europe and Egypt.
Patient selection: ECOG performance status 0 to 2
Outcomes:
(1) progression-free survival (PFS)
(2) overall survival (OS)
Parameters:
(1) epithelial component in histology
(2) stage
(3) ECOG performance stage
Parameter |
Finding |
Points for PFS |
Points for OS |
epithelial component |
yes |
0 |
0 |
|
no |
42 |
44 |
stage |
Stage 1 to 3 |
0 |
0 |
|
Stage 4 |
37 |
38 |
ECOG performance |
0 |
0 |
0 |
|
1 |
50 |
50 |
|
2 |
100 |
100 |
total score for PFS =
= SUM(points for all 3 parameters)
total score for OS =
= SUM(points for all 3 parameters)
Interpretation:
• minimum scores: 0
• maximum score for PFS: 179
• maximum score for OS: 182
probability of 6 month progression-free survival in percent =
= (0.000583 * ((PFS points)^2)) - (0.3141 * (PFS points)) + 40.3
probability of 6 month overall survival in percent =
= (-0.000662 * ((OS points)^2)) - (0.2001 * (OS points)) + 82.57
Specialty: Hematology Oncology, Surgery, general, Pulmonology